Half-year report · HY

Period2025-10-01 → 2026-03-31
Filed2026-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥18.9bn2025-10-01 → 2026-03-31Cons.Net sales
Revenue¥34.4bn2024-10-01 → 2025-09-30Cons.Net sales (5-year summary)
Revenue¥17.8bn2024-10-01 → 2025-03-31Cons.Net sales
Operating income¥530m2025-10-01 → 2026-03-31Cons.Operating income
Operating income¥325m2024-10-01 → 2025-03-31Cons.Operating income
Ordinary income¥565m2025-10-01 → 2026-03-31Cons.Ordinary income
Ordinary income¥595m2024-10-01 → 2025-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥355m2024-10-01 → 2025-03-31Cons.Ordinary income
Profit before tax¥576m2025-10-01 → 2026-03-31Cons.Income before income taxes
Profit before tax¥400m2024-10-01 → 2025-03-31Cons.Income before income taxes
Net income (owners)¥396m2025-10-01 → 2026-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥429m2024-10-01 → 2025-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥269m2024-10-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income¥400m2025-10-01 → 2026-03-31Cons.Profit loss
Net income¥273m2024-10-01 → 2025-03-31Cons.Profit loss
Total assets¥20.4bnat 2026-03-31Cons.Assets
Total assets¥18.4bnat 2025-09-30Cons.Assets
Total assets¥18.5bnat 2025-03-31Cons.Total assets (5-year summary)
Total liabilities¥11.8bnat 2026-03-31Cons.Liabilities
Total liabilities¥10.4bnat 2025-09-30Cons.Liabilities
Net assets / equity¥8.5bnat 2026-03-31Cons.Net assets
Net assets / equity¥8.0bnat 2025-09-30Cons.Net assets
Net assets / equity¥7.7bnat 2025-03-31Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2026-03-31Cons.Cash and deposits
Cash and deposits¥925mat 2025-09-30Cons.Cash and deposits
Cash & equivalents¥3.7bnat 2026-03-31Cons.Cash and cash equivalents
Cash & equivalents¥911mat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.5bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-09-30vCons.Cash and cash equivalents
Operating cash flow¥2.9bn2025-10-01 → 2026-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥150m2024-10-01 → 2025-09-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥674m2024-10-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥33m2025-10-01 → 2026-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥19m2024-10-01 → 2025-09-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥62m2024-10-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥53m2025-10-01 → 2026-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3m2024-10-01 → 2025-09-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2024-10-01 → 2025-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥439.522025-10-01 → 2026-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥475.932024-10-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥298.42024-10-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio41.5%at 2026-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio43.0%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio40.9%at 2025-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Academia Life Science Sales Groupreportable segmentrevenue2025-10-01 → 2026-03-31¥1.3bn
Academia Life Science Sales Groupreportable segmentrevenue external2025-10-01 → 2026-03-31¥1.3bn
Industry Sales Groupreportable segmentrevenue2025-10-01 → 2026-03-31¥9.6bn
Industry Sales Groupreportable segmentrevenue external2025-10-01 → 2026-03-31¥9.6bn
Medical Sales Groupreportable segmentrevenue2025-10-01 → 2026-03-31¥8.0bn
Medical Sales Groupreportable segmentrevenue external2025-10-01 → 2026-03-31¥8.0bn
—segment totalrevenue2025-10-01 → 2026-03-31¥18.9bn
—segment totalrevenue external2025-10-01 → 2026-03-31¥18.9bn
Academia Life Science Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥1.5bn
Academia Life Science Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥1.5bn
Industry Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥9.1bn
Industry Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥9.1bn
Medical Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥7.2bn
Medical Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥7.2bn
—segment totalrevenue2024-10-01 → 2025-03-31¥17.8bn
—segment totalrevenue external2024-10-01 → 2025-03-31¥17.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Number of shares heldInterimInstant_No2MajorShareholdersMember85400
Shareholding ratioInterimInstant_No2MajorShareholdersMember0.095
Number of shares heldInterimInstant_No3MajorShareholdersMember50800
Shareholding ratioInterimInstant_No3MajorShareholdersMember0.056
Number of shares heldInterimInstant_No4MajorShareholdersMember46840
Shareholding ratioInterimInstant_No4MajorShareholdersMember0.052
Number of shares heldInterimInstant_No5MajorShareholdersMember41060
Shareholding ratioInterimInstant_No5MajorShareholdersMember0.046
Number of shares heldInterimInstant_No6MajorShareholdersMember32200
Shareholding ratioInterimInstant_No6MajorShareholdersMember0.036
Number of shares heldInterimInstant_No7MajorShareholdersMember30200
Shareholding ratioInterimInstant_No7MajorShareholdersMember0.034
Number of shares heldInterimInstant_No8MajorShareholdersMember22000
Shareholding ratioInterimInstant_No8MajorShareholdersMember0.024
Number of shares heldInterimInstant_No9MajorShareholdersMember20400
Shareholding ratioInterimInstant_No9MajorShareholdersMember0.023
Number of shares heldInterimInstant_No10MajorShareholdersMember19790
Shareholding ratioInterimInstant_No10MajorShareholdersMember0.022
Number of shares heldInterimInstant438290
Shareholding ratioInterimInstant0.487
Number of shares issued shares voting rightsInterimInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember59000
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember899200
Number of voting rights issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember8992
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesLessThanOneUnitMember1800
Number of shares issued shares voting rightsInterimInstant960000
Number of voting rights issued shares voting rightsInterimInstant8992
Number of shares held in own name treasury shares etcInterimInstant_Row1Member59000
Number of shares held in others names treasury shares etcInterimInstant_Row1Member-
Total number of shares held treasury shares etcInterimInstant_Row1Member59000
Shareholding ratio treasury shares etcInterimInstant_Row1Member0.061
Number of shares held in own name treasury shares etcInterimInstant59000
Number of shares held in others names treasury shares etcInterimInstant-
Total number of shares held treasury shares etcInterimInstant59000
Shareholding ratio treasury shares etcInterimInstant0.061
Cash and depositsPrior1YearInstant924596000JPY
Cash and depositsInterimInstant3718637000JPY
Notes and accounts receivable trade and contract assetsPrior1YearInstant10075953000JPY
Notes and accounts receivable trade and contract assetsInterimInstant8772491000JPY
Electronically recorded monetary claims operating caPrior1YearInstant383143000JPY
Electronically recorded monetary claims operating caInterimInstant330878000JPY
MerchandisePrior1YearInstant1050773000JPY
MerchandiseInterimInstant1224319000JPY
Lease investment assets caPrior1YearInstant81204000JPY
Lease investment assets caInterimInstant78613000JPY
Other caPrior1YearInstant315069000JPY
Other caInterimInstant299918000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-09-30pass
balance sheet identityconsolidated 2026-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net assetsconsolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-10-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-10-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-10-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-10-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-10-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-10-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass
statement vs summary · total assetsconsolidated 2026-03-31pass